Clinical benefit of new targeted agents in phase I trials in patients with advanced colorectal cancer.

Arkenau, Hendrik-Tobias; Brunetto, Andre T; Barriuso, Jorge; Olmos, David; Eaton, David; de Bono, Johann; Judson, Ian; Kaye, Stan

Arkenau, Hendrik-Tobias; Brunetto, Andre T; Barriuso, Jorge; Olmos, David; Eaton, David; de Bono, Johann; Judson, Ian; Kaye, Stan.

Affiliation

Arkenau HT; Drug Development Unit, Royal Marsden Hospital, London and Surrey, UK. hendrik-tobias.arkenau@icr.ac.uk

Oncology ; 76(3): 151-6, 2009.

Article in En | MEDLINE | ID: mdl-19169046

Subject(s)

Antineoplastic Agents/therapeutic use; Clinical Trials, Phase I as Topic; Colorectal Neoplasms/drug therapy; Adult; Aged; Colorectal Neoplasms/mortality; Female; Humans; Male; Middle Aged; Prognosis; Retrospective Studies

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Colorectal Neoplasms / Clinical Trials, Phase I as Topic / Antineoplastic Agents Type of study: Observational_studies / Prognostic_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Oncology Year: 2009 Type: Article Affiliation country: United kingdom

Fulltext

XML

PubMed Links

Search on Google